The use of carbapenems in the treatment of serious infections (Q37555757)

21 August 2017

1 reference

title

The use of carbapenems in the treatment of serious infections (English)

1 reference

21 August 2017

carbapenem antibiotic

0 references

author name string

Robert P Baughman

series ordinal

1

1 reference

21 August 2017

17 July 2009

1 reference

Journal of Intensive Care Medicine

21 August 2017

1 reference

21 August 2017

24

1 reference

21 August 2017

4

1 reference

21 August 2017

230-241

1 reference

Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients

21 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Validation of different techniques for the diagnosis of ventilator-associated pneumonia. Comparison with immediate postmortem pulmonary biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Bronchoscopic BAL in the diagnosis of ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Influence of the MexA-MexB-oprM multidrug efflux system on expression of the MexC-MexD-oprJ and MexE-MexF-oprN multidrug efflux systems in Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Ventilator-associated pneumonia patients who do not reduce bacteria from the lungs have a worse prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Overview of nosocomial infections caused by gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Survey of the susceptibility of urinary isolates to antibacterial agents in 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Antimicrobial resistance in intensive care units

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Clinical outcome of bacteremic spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

AmpC beta-lactamases: what do we need to know for the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Plasmid-determined AmpC-type beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Determinants of the activity of beta-lactamase inhibitor combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Controversies about extended-spectrum and AmpC beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

SHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacae

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Ventilator-associated pneumonia caused by potentially drug-resistant bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Multidrug-resistant Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Appropriate and timely empirical antimicrobial treatment of icu infections--a role for carbapenems

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Respiratory nosocomial infections in the medical intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Epidemiology and microbiology of hospital-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Clinical and economic consequences of ventilator-associated pneumonia: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Experience with a clinical guideline for the treatment of ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Nosocomial infections adversely affect the outcomes of patients with serious intraabdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Aminoglycosides for intra-abdominal infection: equal to the challenge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Beta-lactam regimens for the febrile neutropenic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Practice guidelines for the management of bacterial meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Postantibiotic effect of imipenem on Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Seizure worsening caused by decreased serum valproate during meropenem therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Acute seizures due to a probable interaction between valproic acid and meropenem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Ertapenem-associated seizures in a peritoneal dialysis patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Is it safe to use carbapenems in patients with a history of allergy to penicillin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

21 January 2018

Acquired carbapenemases

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Emergence of resistance to imipenem in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Of Pseudomonas, porins, pumps and carbapenems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0885066609335660

21 January 2018

Identifiers

DOI

10.1177/0885066609335660

1 reference

21 August 2017

1 reference

PubMed ID

19617229